A nationwide study of metabolic syndrome prevalence in Iran; a comparative analysis of six definitions.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2021
Historique:
received: 11 03 2020
accepted: 22 10 2020
entrez: 3 3 2021
pubmed: 4 3 2021
medline: 1 9 2021
Statut: epublish

Résumé

To integrate and execute a proper preventive plan and reduce the risk of non-communicable diseases (NCDs), policy makers need to have access to both reliable data and a unique definition of metabolic syndrome (MetS). This study was conducted on the data collected by cross-sectional studies of WHO's STEPwise approach to surveillance of NCD risk factors (STEPs) to estimate the national and sub-national prevalence rates of MetS in Iran in 2016. The prevalence of MetS was estimated among 18,414 individuals aged ≥25 years living in urban and rural areas of Iran using various definition criteria; National Cholesterol Education Program Adult Treatment Panel III 2004 (ATP III), International Diabetes Federation (IDF), American Heart Association/National Heart, Lung, and Blood Institute (AHA/NHLBI), Joint Interim Statement (JIS). Regional IDF (RIDF) and JIS (RJIS) were defined using ethnicity-specific values of waist circumference for the country. National prevalence rate of MetS based on ATP III, IDF, AHA/NHLBI, JIS, RIDF and RJIS criteria were 38.3% (95% CI 37.4-39.1), 43.5% (42.7-44.4), 40.9% (40.1-41.8), 47.6% (46.8-48.5), 32.0% (31.2-32.9), and 40.8% (40.0-41.7), respectively. The prevalence was higher among females, in urban residents, and those aged 65-69 years. MetS was expected to affect about 18.7, 21.3, 20.0, 23.3, 15.7, and 20.0 million Iranians, respectively, based on ATP III, IDF, AHA/NHLBI, JIS, RIDF and RJIS. The two most common components noted in this population were reduced high-density lipoprotein cholesterol (HDL-C) levels and central obesity. High prevalence rate of MetS among Iranian adults is alarming, especially among females, urban residents, and the elderly. The JIS definition criteria is more appropriate to determine higher number of Iranians at risk of NCDs. Proper management and prevention of MetS is required to adopt multiple national plans including lifestyle modifications, medical interventions, and public education on NCDs risk factors.

Identifiants

pubmed: 33657130
doi: 10.1371/journal.pone.0241926
pii: PONE-D-20-07120
pmc: PMC7928520
doi:

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0241926

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Pak J Med Sci. 2015 Nov-Dec;31(6):1377-82
pubmed: 26870100
Biochem Med (Zagreb). 2012;22(3):276-82
pubmed: 23092060
Arterioscler Thromb Vasc Biol. 2004 Feb;24(2):e13-8
pubmed: 14766739
Lancet. 2005 Sep 24-30;366(9491):1059-62
pubmed: 16182882
Arch Iran Med. 2010 Sep;13(5):426-8
pubmed: 20804311
Eur J Clin Nutr. 2007 Apr;61(4):548-53
pubmed: 17119546
PLoS Med. 2010 Apr 27;7(4):e1000268
pubmed: 20436961
Diabetes Metab Syndr. 2014 Jul-Sep;8(3):170-6
pubmed: 25220921
Int J Public Health. 2014 Apr;59(2):231-41
pubmed: 24346180
Arch Iran Med. 2014 Jan;17(1):54-61
pubmed: 24444064
Arch Iran Med. 2017 Sep;20(9):608-616
pubmed: 29048923
Am J Cardiol. 1988 Aug 1;62(4):345-6
pubmed: 3165237
Circulation. 2004 Jul 13;110(2):227-39
pubmed: 15249516
Diabetes Care. 2009 Jun;32(6):1092-7
pubmed: 19279302
Endocrine. 2008 Feb;33(1):9-20
pubmed: 18338272
Diabet Med. 2010 May;27(5):593-7
pubmed: 20536958
Circulation. 2009 Oct 20;120(16):1640-5
pubmed: 19805654
Diabetes Care. 2011 Jan;34(1):216-9
pubmed: 20889854
JAMA. 2016 Jun 7;315(21):2284-91
pubmed: 27272580
Lancet. 2019 May 11;393(10184):1984-2005
pubmed: 31043324
Metab Syndr Relat Disord. 2013 Oct;11(5):309-18
pubmed: 23734759
BMC Public Health. 2019 Sep 13;19(1):1266
pubmed: 31519165
Indian J Endocrinol Metab. 2012 Jan;16(1):67-71
pubmed: 22276254
Acta Med Iran. 2016 Jun;54(6):370-5
pubmed: 27306343
Int J Cardiol. 2018 May 15;259:216-219
pubmed: 29472026
Front Endocrinol (Lausanne). 2020 Feb 26;11:42
pubmed: 32174887
Ethiop J Health Sci. 2017 Jan;27(1):77-84
pubmed: 28458493
J Phys Act Health. 2015 Jan;12(1):68-73
pubmed: 25760431
Am Heart J. 2004 Jan;147(1):106-12
pubmed: 14691427
Diabetes Metab Syndr. 2016 Jan-Mar;10(1):19-22
pubmed: 26341930
Int J Cardiol. 2013 Sep 20;168(1):369-74
pubmed: 23041003
BMC Public Health. 2017 Jan 21;17(1):101
pubmed: 28109251
Sci Rep. 2019 May 28;9(1):7937
pubmed: 31138853
Diabetes Metab Syndr. 2018 Apr - Jun;12(2):195-201
pubmed: 29203060
Metab Syndr Relat Disord. 2009 Jun;7(3):221-9
pubmed: 19320557
Prev Med. 2013 Dec;57(6):867-71
pubmed: 24103567

Auteurs

Ozra Tabatabaei-Malazy (O)

Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.

Sahar Saeedi Moghaddam (S)

Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.

Nazila Rezaei (N)

Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.

Ali Sheidaei (A)

Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.

Mohammad Javad Hajipour (MJ)

Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Persian Gulf Marine Biotechnology Research Center, The Persian Gulf Biomedical Sciences Research Institute, Bushehr University of Medical Sciences, Bushehr, Iran.

Negar Mahmoudi (N)

Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.

Zohreh Mahmoudi (Z)

Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.

Arezou Dilmaghani-Marand (A)

Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.

Kamyar Rezaee (K)

Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.

Mahdi Sabooni (M)

Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Reference Health Laboratory, Ministry of Health and Medical Education, Tehran, Iran.

Farideh Razi (F)

Diabetes Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.

Farzad Kompani (F)

Division of Hematology and Oncology, Children's Medical Center, Pediatrics Center of Excellence, Tehran University of Medical Sciences, Tehran, Iran.

Alireza Delavari (A)

Digestive Oncology Research Center, Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.

Bagher Larijani (B)

Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.

Farshad Farzadfar (F)

Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH